Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1992 1
1993 1
1994 3
1995 2
1997 12
1998 5
1999 6
2000 2
2001 5
2002 6
2003 7
2004 6
2006 6
2007 5
2009 2
2010 1
2011 1
2013 1
2014 3
2015 5
2016 8
2017 5
2018 5
2019 12
2020 7
2021 5
2022 6
2023 3
2024 6
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

125 results

Results by year

Filters applied: . Clear all
Page 1
Early downmodulation of tumor glycolysis predicts response to fasting-mimicking diet in triple-negative breast cancer patients.
Ligorio F, Vingiani A, Torelli T, Sposetti C, Drufuca L, Iannelli F, Zanenga L, Depretto C, Folli S, Scaperrotta G, Capri G, Bianchi GV, Ferraris C, Martelli G, Maugeri I, Provenzano L, Nichetti F, Agnelli L, Lobefaro R, Fucà G, Fotia G, Mariani L, Morelli D, Ladisa V, De Santis MC, Lozza L, Trecate G, Belfiore A, Brich S, Bertolotti A, Lorenzini D, Ficchì A, Martinetti A, Sottotetti E, Arata A, Corsetto P, Sorrentino L, Rediti M, Salvadori G, Minucci S, Foiani M, Apolone G, Pagani M, Pruneri G, de Braud F, Vernieri C. Ligorio F, et al. Among authors: martinetti a. Cell Metab. 2025 Feb 4;37(2):330-344.e7. doi: 10.1016/j.cmet.2024.11.004. Epub 2024 Dec 17. Cell Metab. 2025. PMID: 39694040 Clinical Trial.
Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO.
Raimondi A, Lonardi S, Murgioni S, Cardellino GG, Tamberi S, Strippoli A, Palermo F, De Manzoni G, Bencivenga M, Bittoni A, Chiodoni C, Lorenzini D, Todoerti K, Manca P, Sangaletti S, Prisciandaro M, Randon G, Nichetti F, Bergamo F, Brich S, Belfiore A, Bertolotti A, Stetco D, Guidi A, Torelli T, Vingiani A, Joshi RP, Khoshdeli M, Beaubier N, Stumpe MC, Nappo F, Leone AG, Pircher CC, Leoncini G, Sabella G, Airo' Farulla L, Alessi A, Morano F, Martinetti A, Niger M, Fassan M, Di Maio M, Kaneva K, Milione M, Nimeiri H, Sposito C, Agnelli L, Mazzaferro V, Di Bartolomeo M, Pietrantonio F. Raimondi A, et al. Among authors: martinetti a. Ann Oncol. 2025 Mar;36(3):285-296. doi: 10.1016/j.annonc.2024.11.016. Epub 2024 Dec 3. Ann Oncol. 2025. PMID: 39637944 Free article. Clinical Trial.
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study.
Niger M, Nichetti F, Fornaro L, Pircher C, Morano F, Palermo F, Rimassa L, Pressiani T, Berardi R, Gardini AC, Sperti E, Salvatore L, Melisi D, Bergamo F, Siena S, Mosconi S, Longarini R, Arcangeli G, Corallo S, Delliponti L, Tamberi S, Fea E, Brandi G, Rapposelli IG, Salati M, Baili P, Miceli R, Ljevar S, Cavallo I, Sottotetti E, Martinetti A, Busset MDD, Sposito C, Di Bartolomeo M, Pietrantonio F, de Braud F, Mazzaferro V. Niger M, et al. Among authors: martinetti a. BMC Cancer. 2024 Apr 8;24(1):436. doi: 10.1186/s12885-024-12225-6. BMC Cancer. 2024. PMID: 38589856 Free PMC article. Clinical Trial.
Chromogranin A measurement in neuroendocrine tumors.
Ferrari L, Seregni E, Martinetti A, Van Graafeiland B, Nerini-Molteni S, Botti C, Artale S, Cresta S, Bombardieri E. Ferrari L, et al. Among authors: martinetti a. Int J Biol Markers. 1998 Jan-Mar;13(1):3-9. doi: 10.1177/172460089801300102. Int J Biol Markers. 1998. PMID: 9681293 Review.
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases.
Marmorino F, Prisciandaro M, Giordano M, Ortolan E, Crucitta S, Manca P, Antoniotti C, Valenti MM, Danesi R, Conca V, Mazzoli G, Boccaccino A, Carullo M, Martinetti A, Sottotetti E, Masi G, Sposito C, Zaffaroni N, Milione M, Fontanini G, Del Re M, Pietrantonio F, Cremolini C. Marmorino F, et al. Among authors: martinetti a. JCO Precis Oncol. 2022 Nov;6:e2200244. doi: 10.1200/PO.22.00244. JCO Precis Oncol. 2022. PMID: 36356286
Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer.
Galli G, Corsetto PA, Proto C, Lo Russo G, Ganzinelli M, Rulli E, Legramandi L, Morelli D, Ferrara R, Prelaj A, Signorelli D, De Toma A, Brambilla M, Occhipinti M, Manglaviti S, Boeri M, Martinetti A, Vingiani A, Colombo MP, Rizzo AM, Torri V, de Braud F, Sangaletti S, Sica A, Garassino MC. Galli G, et al. Among authors: martinetti a. Clin Lung Cancer. 2022 Nov;23(7):e489-e499. doi: 10.1016/j.cllc.2022.07.010. Epub 2022 Jul 21. Clin Lung Cancer. 2022. PMID: 35948460
125 results